Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Major Depressive Disorder (MDD
Phase NA
Enrollment 338
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to investigate the efficacy of a psychoeducational program as an adjunctive treatment for depression. The study will involve 338 patients diagnosed with Major Depressive Disorder (MDD) of moderate severity. Participants will be randomly assigned to receive either Treatment as usual (TAU) alone or TAU plus the psychoeducational program. The program consists of six weekly group sessions covering information and techniques for coping with depression. Primary outcomes include a reduction in depressive symptoms measured by the Beck Depression Inventory-II (BDI-II) and increased knowledge of depression. Secondary outcomes include improvements in functionality and quality of life. The study aims to provide insights into the effectiveness of psychoeducation in improving outcomes for individuals with depression

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: PEG-D program — PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.
  • Drug: TAU — The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\'s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.

Primary Outcomes

  • Knowledge level (Time: baseline, post 6 weeks and 12 months.)
  • Depressive levels (Baseline, post 6 weeks, 3, 6 and 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-01
Completion: 2026-12-01
Eligibility
Age: 18 Years – 59 Years
Sex: ALL
Volunteers: false
Enrollment: 338 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ricardo Alberto Moreno, M.D., Ph.D.
Contact Information
Study Contact:
Ricardo A Moreno
55-2661-6648
ricardo.moreno@hc.fm.usp.br
Institute of Psychiatry IPqFMUSP Moreno, RA, PhD
55-112661-6648
grudaipq@hc.fm.usp.br
Institute of Psychiatry - Faculty of Medicine from University of Sao Paulo
Adriana Carneiro AM Adriana Carneiro, DsC.
psicoeducacaogruda@gmail.com
Institute of Psychiatry - Faculty of Medicine from University of Sao Paulo
Interventions
  • Behavioral: PEG-D program — PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.
  • Drug: TAU — The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\'s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.
Study Locations (1 sites)
Institute of Psychiatry - Faculty of Medicine from University of Sao Paulo, São Paulo, 05403903 Brazil
Eligibility Criteria
Inclusion: * Both sexes; * Ages between 18 and 65 years old; * Diagnosis of Major Depressive Disorder (MDD) made by a clinician according to Diagnostic Statistical Manual criteria-5-Text Revised (DSM-5-TR) * Patients with Hamilton Depressive Rating Scale-17 items (HDRS-17) scores 14-23; * Informed and signed consent form. Exclusion: * Unstable serious clinical or neurological diseases; * Postpartum depression or other types of depressive disorders (disruptive mood dysregulation disorder, pre-menstrual, substance/medication-induced depressive disorder, depressive disorder due to another medical condition, another disorder specified depressive disorder and unspecified depressive disorder); * Other psychiatric disorders; * Patients with active psychotic symptoms; * Suicidality risks * Patients already undergoing any other psychological treatment for MDD; Discontinuation: * More than two absences during treatment; * Those who miss more than two sessions/consultations, whether medical treatment or the psychoeducational program; * Non-response to the use of Sertraline over the initial eight weeks; Presence of hypomanic symptoms at any time during treatment (Young \<7)
Conditions Thyroid Disorders Complicating Pregnancy...
Phase Not Applicable
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This prospective, single-center, observational cross-sectional study aims to evaluate the relationship between thyroid-stimulating hormone (TSH) levels and psychological as well as sexual health outcomes during pregnancy. Pregnant individuals will undergo psychometric assessment using the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), the Arizona Sexual Experience Scale (ASEX), and the YKK-13 Quality of Life Scale. The study will investigate whether maternal TSH levels are associated with depression, anxiety, sexual function, and overall quality of life scores. Eligible participants will be pregnant women aged 18-45 years with a singleton pregnancy of at least 6 weeks, who are literate and have provided informed consent. Individuals with a prior psychiatric history, multiple gestation, or existing systemic or endocrine diseases will be excluded. The primary endpoint of the study is to determine the association between TSH levels and psychometric scale scores during pregnancy.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Association Between TSH Levels and Psychometric Scale Scores (At enrollment (single visit).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-01
Completion: 2025-12-01
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gaziosmanpasa Research and Education Hospital
Principal Investigators:
  • havva betül bacak, md (PRINCIPAL_INVESTIGATOR) - SBÜ Gaziosmanpaşa Training and Research Hospital
Contact Information
Study Contact:
havva betül bacak, md
+905333610088
hbbacak90@gmail.com
fatih irice, md
5055434973
fatihirice@gmai.com
havva betül bacak, md
+905333610088
hbbacak90@gmail.com
SBÜ Gaziosmanpaşa Training and Research Hospital
Interventions
N/A
Study Locations (1 sites)
SBÜ Gaziosmanpaşa Training and Research Hospital, Istanbul, Gaziosmanpaşa 33400 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: Pregnant women aged 18-45 years Singleton pregnancy Gestational age ≥ 6 weeks Literacy and ability to provide informed consent Availability of a TSH result obtained within the past 4 weeks Cognitive ability sufficient to complete the psychometric questionnaires (Beck Depression Inventory, Beck Anxiety Inventory, ASEX, and YKK-13 Quality of Life Scale) Exclusion Criteria: Multiple pregnancy Previously diagnosed psychiatric disorder or active use of antidepressant/ anxiolytic medication Current treatment for thyroid disease History of thyroid surgery Major systemic illness or significant obstetric complications Age under 18 years or inability to provide informed consent Inability to complete the questionnaires adequately (missing or invalid data) Rationale: Multiple pregnancies are excluded because they differ significantly from singleton pregnancies in terms of hormonal profile, obstetric risks, and psychological stress levels. This exclusion aims to ensure a homogeneous study population.
Conditions Anxiety Disorders, Depressive Disorder, ...
Phase NA
Enrollment 202
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn about how psychotherapy works for children and adolescents aged 8 - 15 with anxiety, depression, trauma, or disruptive behaviour. The main question it aims to answer is: • Is the biobehavioural regulation of negative emotion a transdiagnostic mechanism of treatment response in psychotherapy for children with anxiety, depression, trauma and/or disruptive behaviour? Children and their parents will be randomly assigned to an evidence-based, transdiagnostic treatment (the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems; MATCH-ADTC) or a waitlist control condition. Participants in both groups will complete a baseline assessment, weekly measures consisting of brief symptom scales and medication tracking, and quarterly assessments every 3 months. Following the intervention/waitlist period, our team will conduct post-test assessments. All assessments, except for the weekly surveys, will consist of symptom scales, clinical interviews, experimental tasks and physiological measures.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems — The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.

Primary Outcomes

  • Change in parent-rated child psychopathology symptoms (Change at quarterly (3 month intervals after pre-test), change at post-test (after completion of the waitlist or intervention treatment; an average range 4 - 6 months))
  • Change in child self-reported psychopathology symptoms (Change at quarterly (3 month intervals after pre-test), change at post-test (after completion of the waitlist or intervention treatment; an average range 4 - 6 months))
  • Change in child psychopathology symptoms (past week) (Change at post-test (after completion of the waitlist or intervention treatment; an average range 4 - 6 months))
  • Change in child emotional-behavioural problems (Change at quarterly (3 month intervals after pre-test), change at post-test (after completion of the waitlist or intervention treatment; an average range 4 - 6 months))
  • Change in child impairment (Change at post-test (after completion of the waitlist or intervention treatment; an average range 4 - 6 months))
  • Change in ratings of child emotion regulation (Change at post-test (after completion of the waitlist or intervention treatment; an average range 4 - 6 months))
  • Change in child physiological emotion regulation (heart rate variability) (Change at quarterly (3 month intervals after pre-test), change at post-test (after completion of the waitlist or intervention treatment; an average range 4 - 6 months))
  • Change in child physiological emotion regulation (skin conductance) (Change at quarterly (3 month intervals after pre-test), change at post-test (after completion of the waitlist or intervention treatment; an average range 4 - 6 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-01
Completion: 2027-12-31
Eligibility
Age: 8 Years – 15 Years
Sex: ALL
Volunteers: false
Enrollment: 202 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Guelph
Collaborators: Centre for Addiction and Mental Health, Canadian Institutes of Health Research (CIHR)
Principal Investigators:
  • Kristel Thomassin, PhD (PRINCIPAL_INVESTIGATOR) - University of Guelph
Contact Information
Study Contact:
Jessica Pun, BA
519-824-4120
punj@uoguelph.ca
Kristel Thomassin, PhD
519-824-4120
Maplewoods Centre for Family Therapy and Child Psychology
Brendan Andrade, PhD
The Centre for Addition and Mental Health
Interventions
  • Behavioral: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems — The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.
Study Locations (2 sites)
Maplewoods Centre for Family Therapy and Child Psychology, Guelph, Ontario N1G 2W1 Canada
The Centre for Addition and Mental Health, Toronto, Ontario Canada
Eligibility Criteria
Inclusion Criteria: * Child must be between the ages of 8 and 15 years old and have English proficiency * Parents must be over the age of 18 and have English proficiency * Must be seeking psychosocial treatment for concerns related to anxiety, depression, or disruptive behaviours Exclusion Criteria: * Child has low cognitive functioning that would prevent active participation in research tasks * Child reports active suicidality that requiring acute care or hospital intervention * Child meets criteria for psychosis, schizophrenia spectrum disorders, eating disorders or autism spectrum disorders * Child does not assent to participate in the study
Conditions Diary (Blank Journal), Intensive Care Un...
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Randomized clinical trial that aims to evaluate the impact of the use of a diary in patients and relatives of patients admitted to an ICU in relation to usual practice in terms of health-related quality of life, the post-traumatic stress and anxiety/depression at 2, 6 and 12 months after ICU discharge.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Other: use of diary — a diary is made for the experimental group where the events and events during the period of sedation and intubation are explained

Primary Outcomes

  • Hospital Anxiety and Depression Scale (HADS) (2 months)
  • Hospital Anxiety and Depression Scale (HADS) (6 months)
  • Hospital Anxiety and Depression Scale (HADS) (12 months)
  • SF-36 Health Survey (2 months)
  • SF-36 Health Survey (6 months)
  • SF-36 Health Survey (12 months)
  • Revised Impact of Event Scales (IES-R) (2 months)
  • Revised Impact of Event Scales (IES-R) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-01-01
Completion: 2026-12-31
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: true
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Barcelona
Contact Information
Study Contact:
Pilar Muñoz Rey
639534904
mpmunozr.germanstrias@gencat.cat
pilar muñoz rey
639534904
mpmunozr.germanstrias@gencat.cat
Universidad de Barcelona
Interventions
  • Other: use of diary — a diary is made for the experimental group where the events and events during the period of sedation and intubation are explained
Study Locations (1 sites)
Universidad de Barcelona, Barcelona, 08185 Spain
Eligibility Criteria
Inclusion Criteria: * admitted intensive care unit * sedated and mechanically ventilated for 24hours * signed consent * not language barrier * willingness to attend follow-up visits Exclusion Criteria: * verbal manifestation of psychiatric, mental or cognitive antecedents * who do not coluntarily agree to participate
Conditions Postpartum Hypertension
Phase NA
Enrollment 6030
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The investigators primary project goal is to improve clinical outcomes, including mental health outcomes, among postpartum at-risk women experiencing health disparities by increasing awareness, detection, and timely care of postpartum hypertension, mental health and cardiovascular complications. The investigators will accomplish this by comparing the effectiveness of two multi-component multi-level healthcare delivery models focused on early detection and control of postpartum hypertension and the social and mental health factors known to impact maternal outcomes, with the current standard of care and with each other.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Remote Medical Model (RMM) — Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive
  • Other: Community Health Model (CHM) — Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.
  • Other: SoC — SoC for Postpartum Hypertension

Primary Outcomes

  • Change in mean postpartum systolic blood pressure (SBP) at 6 weeks (6 weeks)
  • Depression severity at 3 months postpartum assessed using the Edinburgh Postnatal Depression Scale (EPDS). (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-12
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 6030 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Rafael Pérez-Escamilla, PhD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Rafael Pérez-Escamilla, PhD
8608052502
rafael.perez-escamilla@yale.edu
Rafael Pérez-Escamilla, PhD
Yale New Haven Hospital
Interventions
  • Other: Remote Medical Model (RMM) — Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive
  • Other: Community Health Model (CHM) — Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.
  • Other: SoC — SoC for Postpartum Hypertension
Study Locations (3 sites)
Yale New Haven Hospital, New Haven, Connecticut 06520 United States
University of Massachusetts Memorial Health, Worcester, Massachusetts 01655 United States
Oishei Children's Hospital University at Buffalo, Buffalo, New York 14203 United States
Eligibility Criteria
Inclusion Criteria: * Delivery of singleton live birth (twins reduced to singleton or with vanishing twin syndrome prior to 14 weeks qualify) * Postpartum * English or Spanish speaking * Viable pregnancy 24 weeks of gestation or above (Child can be in NICU to participate) * Medicaid or the equivalent within each state (for example, Connecticut has Husky insurance) or uninsured * Must living in one of the three states involved in this study (Connecticut, Massachusetts, New York) and preferably within the geographical area of each of the hospitals Exclusion Criteria: * Multifetal pregnancy (since are they at increased risk for key outcomes) * Gestational age \<24 weeks; * Known major fetal anomaly in current pregnancy or stillbirth * Actively using illicit/illegal substances (such as cocaine, heroin and other types of illicit opiates such as fentanyl) as noted in delivery hospitalization notes * Active suicidal ideation with intent and plan * Known primary psychotic disorder (i.e. schizophrenia, or schizoaffective disorder) * Plans to move out of the state within 6 months * Incapable of consent * Severe medical complications that don't allow a mother to do the study effectively (for example, active treatment for cancer, dialysis etc. ) * Physician or provider refusal * Patient refusal * Incarcerated or institutionalized * Stillbirth Births that result in the newborn being under the care of another person or institution other than the birthing individual (e.g. adoption, state involvement) will be evaluated on an individual basis to determine if that person should be included. For participants without access to a phone, we will explore if there are options that will allow them to have access to a devise for the times when they need to communicate with the study team. If not, they will not be able to participate in the study since this study requires phone or telehealth communication with research staff and/or APPs, and CHWs depending on study phase.
Conditions Hypertension in Pregnancy, Hypertension,...
Phase NA
Enrollment 144
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

High blood pressure during pregnancy poses significant risks to both the mother and baby. A combination of factors, including advancing maternal age, rising obesity rates, and metabolic health issues, have amplified the prevalence of this condition. While conventional medicines are available, safety during pregnancy remains a concern. Recent studies suggest that inorganic nitrate might be a safer alternative. The power of nitrate lies in its ability to stimulate the body's production of a compound that aids in dilating and relaxing blood vessels. Preliminary studies conducted on mice and a select group of pregnant women have yielded encouraging results. Early tests indicated that after consuming inorganic nitrate, there was a reduction in blood pressure and an improvement in the health of the mother's uterine artery-a vital vessel responsible for nourishing the fetus. Our study aims to investigate the effects of inorganic nitrate supplementation on pregnant women from the start of their pregnancy and continuing it throughout their term. If our findings are positive, it could revolutionize how we approach blood pressure management during pregnancy, paving the way for healthier futures for both mothers and babies.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Inorganic Nitrate Capsule — Starting from the 16th week of gestation and continuing for 22 weeks (154 days) or until delivery, whichever comes first, participants will consume a daily capsule containing 400 mg of inorganic nitrate. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
  • Dietary Supplement: Placebo Capsule — From the 16th week of gestation and lasting 22 weeks (154 days) or until delivery, participants will consume a daily capsule containing sodium chloride with the nitrate replaced by plant-based flour, design to mimic the appearance of the active capsule. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.

Primary Outcomes

  • Blood Pressure Control in Chronic Hypertensive Pregnant Women with Inorganic Nitrate Supplementation Compared to Placebo. (From baseline (16th week) up to delivery)
  • Increased Antihypertensive Medication Requirements in Patient Groups (From baseline (16th week) up to delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-06
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 144 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo
Collaborators: Hospital das Clínicas de Ribeirão Preto
Principal Investigators:
  • Ricardo C Cavalli, Dr (PRINCIPAL_INVESTIGATOR) - Medical School of Ribeirao Preto, USP
Contact Information
Study Contact:
Ricardo C Cavalli, Dr
+55166021000
rcavalli@fmrp.usp.br
Priscila O Barbosa, Dr
+5531971349289
barbosapo@usp.br
PRISCILA O BARBOSA, Dr
+5531971349289
barbosapo@usp.br
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
Interventions
  • Dietary Supplement: Inorganic Nitrate Capsule — Starting from the 16th week of gestation and continuing for 22 weeks (154 days) or until delivery, whichever comes first, participants will consume a daily capsule containing 400 mg of inorganic nitrate. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
  • Dietary Supplement: Placebo Capsule — From the 16th week of gestation and lasting 22 weeks (154 days) or until delivery, participants will consume a daily capsule containing sodium chloride with the nitrate replaced by plant-based flour, design to mimic the appearance of the active capsule. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
Study Locations (1 sites)
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, São Paulo Brazil
Eligibility Criteria
Inclusion Criteria: * Pregnant women diagnosed with chronic hypertension (systolic blood pressure above 140 mmHg and/or diastolic blood pressure above 90 mmHg before pregnancy or before 20 weeks of gestation) as defined by the Brazilian Network for Studies on Hypertension in Pregnancy (RBEHG, Brazilian acronym) Protocol and Chronic Hypertension/Preeclampsia by the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO, Brazilian acronym) Protocol. * Patients on monotherapy with methyldopa as treatment at the time of inclusion. * Women with less than 16 weeks of gestation confirmed by first-trimester ultrasonography confirming gestational age. Exclusion Criteria: * Multiple pregnancies, age below 18 years old, inability to provide informed consent, or history of low adherence to medication therapy. * Patients with uncontrolled chronic hypertension, with blood pressure values above 160x110mmHg. * History of food allergies, especially hypersensitivity to beetroot. * Users of illicit drugs, smokers, or alcohol abusers. * Diagnosis of coronary artery disease, congestive heart failure (moderate to severe), moderate to severe liver failure, chronic renal insufficiency (with plasma creatinine clearance less than 30 ml/min/1.73 m² of body surface), pre-existing type 1 diabetes, and type 2 diabetes. * Pregnant women who frequently used non-steroidal anti-inflammatory drugs, nasal decongestants, and anorectics before getting pregnant; users of proton pump inhibitors and H2 receptor antagonists or any other medication that interferes with stomach pH, starting 2 weeks before the beginning and continuing throughout the remainder of the study.
Conditions Arterial Pulmonary Hypertension (PAH)
Phase Not Applicable
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs — Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.

Primary Outcomes

  • Pulmonary Vascular Resistance (PVR) (Up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-10
Completion: 2027-02-14
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Qianfoshan Hospital
Collaborators: Chinese Academy of Medical Sciences, Fuwai Hospital, Jianghan University Affiliated Hospital
Contact Information
Study Contact:
Guanghai Wang, Prof.
+86 18553136966
224138908@qq.com
Guanghai Wang
18553136966
224138908@qq.com
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
Interventions
  • Drug: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs — Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.
Study Locations (1 sites)
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014 China
Eligibility Criteria
Inclusion Criteria: * Consent and sign the informed consent form * Non-low-risk PAH treatment-naive patients Exclusion Criteria: * Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension * Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary * Pregnant or lactating women * Suffering from mental illness or cognitive impairment * PAH patients with concurrent malignant tumors * Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia * Currently participating in other interventional clinical studies * Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.
Conditions Hypertension
Phase PHASE2
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to determine if the medication eplerenone yields greater improvements in coronary microvascular function than chlorthalidone in women who experienced preeclampsia during pregnancy and subsequently developed chronic hypertension. The main Aims are: * To test the hypothesis that, in women with prior preeclampsia, current chronic hypertension, and concentric LV remodeling, eplerenone improves coronary microvascular function vs. chlorthalidone. * To test the hypothesis that, in women with prior preeclampsia, current chronic hypertension, and concentric LV remodeling, eplerenone improves cardiac structure and function vs. chlorthalidone. Participants will: * First receive pre-treatment with Amlodipine for 12 weeks prior to beginning the study medication. * Start study treatment which involves daily self-administration of two oral capsules (eplerenone + potassium placebo or chlorthalidone + potassium), each taken once a day, for a total of 336 doses over 48 weeks. * Attend study visits at weeks 2, 12, 24, 36, and 48. These visits will involve collecting information, measuring blood pressure, and gathering blood and urine samples. Echocardiography (cardiac ultrasound), eye exam, and cardiac PET/CT scan will be performed during the baseline and week 48 visits.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Eplerenone 100 mg daily — Participants with a history of preeclampsia and current chronic hypertension will receive 100mg capsules of eplerenone to self-administer daily over the 48-week duration of the study treatment.
  • Drug: Chlorthalidone 25 mg daily — Participants with a history of preeclampsia with current chronic hypertension will receive 25mg capsules of chlorthalidone to self-administer daily over the 48-week duration of the study treatment.
  • Drug: Potassium Placebo — Participants taking eplerenone will also take a potassium placebo to self-administer daily over the 48-week duration of the study treatment.
  • Drug: Potassium Chloride — Participants taking chlorthalidone will also take 20 mEq of potassium to self-administer daily over the 48-week duration of the study treatment.

Primary Outcomes

  • Change in Myocardial Flow Reserve (MFR) (Prior to randomization and after 48 weeks of randomized study treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-20
Completion: 2029-03-30
Eligibility
Age: 18 Years – 65 Years
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: Brigham and Women's Hospital, National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Michael Honigberg, MD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Pearl Lee, MSc
617-721-7783
plee23@mgh.harvard.edu
Ellen Seely, MD
617-732-5666
ESEELY@bwh.harvard.edu
Brigham and Women's Hospital
Pearl Lee, MSc
617-721-7783
plee23@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Drug: Eplerenone 100 mg daily — Participants with a history of preeclampsia and current chronic hypertension will receive 100mg capsules of eplerenone to self-administer daily over the 48-week duration of the study treatment.
  • Drug: Chlorthalidone 25 mg daily — Participants with a history of preeclampsia with current chronic hypertension will receive 25mg capsules of chlorthalidone to self-administer daily over the 48-week duration of the study treatment.
  • Drug: Potassium Placebo — Participants taking eplerenone will also take a potassium placebo to self-administer daily over the 48-week duration of the study treatment.
  • Drug: Potassium Chloride — Participants taking chlorthalidone will also take 20 mEq of potassium to self-administer daily over the 48-week duration of the study treatment.
Study Locations (2 sites)
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Massachusetts General Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: * Female with a history of preeclampsia (defined by ACOG criteria) in a singleton pregnancy without pre-gestational chronic hypertension. * Current chronic hypertension (stage 1 or greater). * Evidence of concentric left ventricular (LV) remodeling, defined as relative LV wall thickness \>0.42, with or without LV hypertrophy. * Age 18-65 years at time of randomization. Exclusion Criteria: * Use of a mineralocorticoid receptor antagonist (MRA) or amiloride within the past 3 months or more than 30 days within the previous 12 months. * Planned pregnancy, current pregnancy, or lactation. * Systolic BP \>150 mmHg and/or diastolic BP \>95 mmHg while on antihypertensives, or systolic BP \>160 mmHg and/or diastolic BP \>100 mmHg if untreated. * BMI \>45 kg/m². * Clinical atherosclerotic cardiovascular disease, including coronary, cerebrovascular, or peripheral artery disease. * Diabetes mellitus. * LV ejection fraction \<40% or history of clinical heart failure (reduced or preserved ejection fraction). * Hypertrophic or other genetic cardiomyopathy. * Any moderate or greater valvular heart disease. * eGFR \<60 mL/min/1.73 m². * Urine microalbumin/creatinine ratio \>300 mg/g at screening. * Abnormal electrolytes, hemoglobin, liver function tests, or TSH at screening or baseline. * Plasma renin activity \<1 mg/mL/hour and aldosterone \>20 ng/dL (suggestive of primary aldosteronism). * Use of oral contraceptives, progestin depot or implant (note: progestin-containing IUD is permitted), or menopausal hormone therapy. * History of hypersensitivity or intolerance to calcium channel blockers, thiazides, or MRAs. * Active substance abuse. * Other serious medical illnesses or concerns about protocol adherence/mortality risk within 15 months. * Participation in another interventional clinical study. * Participants using GLP-1 receptor agonists (GLP-1RA) are eligible only if they have received continuous treatment with the same GLP-1RA agent at an unchanged maintenance dose for ≥12 months prior to enrollment. Dose changes, agent switches, or formulation changes within the 12 months preceding enrollment are not permitted. Temporary interruptions of ≤4 consecutive weeks (e.g., due to supply issues or procedural holds) are allowed, provided the same agent and dose are resumed. At the time of enrollment, there must be no planned or anticipated GLP-1RA dose escalation, dose reduction, or discontinuation. Initiation of GLP-1RA therapy after randomization is not permitted. Dose changes during follow-up are discouraged unless clinically required. * Use of allopurinol. * Use of lithium.
Conditions Hypertension in Pregnancy, Postpartum Pr...
Phase NA
Enrollment 1536
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is a hybrid type 1 non-inferiority implementation effectiveness trial among postpartum patients with hypertension (N=1536) that will test the hypothesis that RI-SPHERES (a technologically enabled collaborative care model) is non-inferior to a standard self-measured blood pressure program in terms of persistent hypertension at six weeks postpartum and preventive care receipt within one year of delivery.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: RI-SPHERES — Participants assigned to the RI-SPHERES group will be introduced virtually or in-person to the care manager (CM), who demonstrate how to communicate directly with patients through the app for medical or non-medical needs. Each participant will learn how to obtain SMBP, sync the LTE-enabled BP cuff to the RI-SPHERES app, and respond to adaptive messaging pertaining to BP measurements, which include the ability to receive on-demand education on postpartum topics (e.g., HDP, breastfeeding, mood disorders) per participant preference. During the study period, the CM will respond to needs elicited from the SDoH screening by facilitating referrals to community resources. After six weeks, the focus of RI-SPHERES will transition to preventive care in addition to SMBP. The CM will engage monthly with each study participant to ensure they have a primary care provider and to facilitate preventive care visits or specialist appointments, if needed.
  • Behavioral: Standard self-measured blood pressure program — Participants assigned to the routine care group meet virtually or in-person with a member of WIH's existing SMBP program and enroll in WIH's EPIC MyChart Portal to allow the SMBP program to receive patient-entered BP measurements and respond to messages. Participants will be provided with BP cuffs and taught how to obtain SMBP and report their BP through MyChart. At six weeks postpartum, WIH SMBP staff send a MyChart message to recommend BP ascertainment once per month and to describe the importance of attending a clinical visit with a primary care provider within a year of birth.

Primary Outcomes

  • Persistent hypertension (Six weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-15
Completion: 2029-03-01
Eligibility
Age: 18 Years – 60 Years
Sex: FEMALE
Volunteers: false
Enrollment: 1536 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Women and Infants Hospital of Rhode Island
Collaborators: Brown University, Kent Hospital, Rhode Island
Contact Information
Study Contact:
Stephanie Nunez, Research Coordinator
401-274-1122
snunez@wihri.org
Emily Blosser, MD, PhD
401-846-6400
eblosser@lifespan.org
Newport Hospital
Stephanie Nunez, BS
401-274-1122
snunez@wihri.org
Women & Infants Hospital of Rhode Island
Interventions
  • Behavioral: RI-SPHERES — Participants assigned to the RI-SPHERES group will be introduced virtually or in-person to the care manager (CM), who demonstrate how to communicate directly with patients through the app for medical or non-medical needs. Each participant will learn how to obtain SMBP, sync the LTE-enabled BP cuff to the RI-SPHERES app, and respond to adaptive messaging pertaining to BP measurements, which include the ability to receive on-demand education on postpartum topics (e.g., HDP, breastfeeding, mood disorders) per participant preference. During the study period, the CM will respond to needs elicited from the SDoH screening by facilitating referrals to community resources. After six weeks, the focus of RI-SPHERES will transition to preventive care in addition to SMBP. The CM will engage monthly with each study participant to ensure they have a primary care provider and to facilitate preventive care visits or specialist appointments, if needed.
  • Behavioral: Standard self-measured blood pressure program — Participants assigned to the routine care group meet virtually or in-person with a member of WIH's existing SMBP program and enroll in WIH's EPIC MyChart Portal to allow the SMBP program to receive patient-entered BP measurements and respond to messages. Participants will be provided with BP cuffs and taught how to obtain SMBP and report their BP through MyChart. At six weeks postpartum, WIH SMBP staff send a MyChart message to recommend BP ascertainment once per month and to describe the importance of attending a clinical visit with a primary care provider within a year of birth.
Study Locations (5 sites)
Newport Hospital, Newport, Rhode Island 02840 United States
Women & Infants Hospital of Rhode Island, Providence, Rhode Island 02903 United States
South County Hospital, Wakefield, Rhode Island 02879 United States
Kent Hospital, Warwick, Rhode Island 02886 United States
Landmark Hospital, Woonsocket, Rhode Island 02895 United States
Eligibility Criteria
Inclusion Criteria: * Postpartum patient aged 18 years or more at any birthing hospital in Rhode Island * Diagnosed during pregnancy or after delivery with hypertensive disorder of pregnant * English-, Spanish-, Portuguese-, or Haitian-Creole-speaking * Smartphone ownership Exclusion Criteria: * Prior enrollment in this trial * Prisoners or incarcerated people * Inability or unwillingness to provide informed consent * Inability to communicate with study team, despite an interpreter
Conditions Hypertension
Phase NA
Enrollment 2160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a prospective, multicenter, single-blind, three-arm parallel-group, cluster randomized controlled trial assessing the effectiveness and safety of two types of CDSS in primary care settings in China. Primary care sites are randomized to one of the intervention arms or the control arm (1:1:1 ratio) using computer-generated random numbers stratified by region and administrative categories of the primary healthcare institutions (including community health centers, community health stations, and township health centers). A total of 51 primary care sites are randomized to three groups, with 17 sites assigned to group A (use a CDSS based on clinical guidelines and machine learning), 17 sites to group B (use a CDSS based on guidelines, hemodynamic parameters and ML), and the remaining 17 sites to the control group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Combination Product: Group A (clinical guideline+machine learning) — Group A (CG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG) and machine learning (ML) approach.
  • Combination Product: Group B (clinical guideline+impedance cardiograph+machine learning) — Group B (CG+ICG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG), hemodynamic parameters measured by impedance cardiograph (ICG), and machine learning (ML) approach.
  • Other: Group C (usual care) — Control group, the physicians manage the hypertensive patients according to their knowledge and experiences.

Primary Outcomes

  • hierarchical composite outcome (Baseline; 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-26
Completion: 2026-05-31
Eligibility
Age: 35 Years – 79 Years
Sex: ALL
Volunteers: false
Enrollment: 2160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China National Center for Cardiovascular Diseases
Principal Investigators:
  • Xin Zheng (PRINCIPAL_INVESTIGATOR) - Fuwai Hospital, China Academy of Medical Sciences, National Center for Cardiovascular Diseases
Contact Information
Study Contact:
Xiaofang Yan
0086 10 60686871
yanxiaofang@fuwai.com
Xin Zheng
0086 10 60866719
zhengxin@fuwai.com
Xiaofang Yan
0086 1358186128
yanxiaofang@fuwai.com
Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences
Interventions
  • Combination Product: Group A (clinical guideline+machine learning) — Group A (CG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG) and machine learning (ML) approach.
  • Combination Product: Group B (clinical guideline+impedance cardiograph+machine learning) — Group B (CG+ICG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG), hemodynamic parameters measured by impedance cardiograph (ICG), and machine learning (ML) approach.
  • Other: Group C (usual care) — Control group, the physicians manage the hypertensive patients according to their knowledge and experiences.
Study Locations (1 sites)
Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Shenzhen China
Eligibility Criteria
Inclusion Criteria: 1. 35 ≤ Age \< 80 years. 2. Regularly attend the clinic for hypertension treatment during the study period, without plans of traveling during the study period. 3. Diagnosed with hypertension, with SBP ≥140mmHg at screening. 4. Currently taking 0 or 2 classes of antihypertensive medications (A/C/D), with or without concurrent use of class B. 5. Willing to participate in the trial and capable of providing written informed consent. Exclusion Criteria: 1. Physician-diagnosed or suspected secondary hypertension (e.g., hypertension caused by renal disease, renal artery stenosis, aortic stenosis, primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid dysfunction, intracranial disease, drug-induced, or rare monogenic genetic disease). 2. SBP ≥180mmHg and/or DBP ≥110mmHg at the screening visit. 3. Suspected or diagnosed white coat hypertension. 4. History of coronary heart disease. 5. History of heart failure. 6. Intolerance to 2 or more classes of A, C,D antihypertensive medications. 7. Currently taking antihypertensive medications other than class A,B,C and D. 8. Diagnosed chronic kidney disease, estimating Glomerular Filtration Rate (eGFR)\< 60 ml/min·1.73m2, or receiving dialysis. 9. Serious medical conditions (e.g., malignant cancer and hepatic dysfunction) 10. Currently in an acute episode of disease (e.g, new-onset cardiovascular and cerebrovascular disease occurred within 3 months). 11. Cognitive or communicative disorders. 12. Currently pregnant or breastfeeding or planning a pregnant or breastfeeding during the study. 13. Reluctant to take antihypertensive medications or have poor compliance with previous treatment. 14. Participating in other clinical trials.
Conditions Glaucoma, Cataract
Phase NA
Enrollment 152
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to investigate postoperative outcomes after two different MIGS implants (MINIject or Hydrus) in combination with cataract surgery for patients with glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: MINIject with Cataract Surgery — Patients will be randomized to receive either a MINIject implant or a Hydrus Microstunt in conjunction with cataract surgery. If randomized to MINIject, the device will be implanted into the supraciliary space with a minimally invasive ab interno approach. It is designed to be implanted with its head in the anterior chamber and its body in the supraciliary space, leading to improved natural uveoscleral outflow by directing aqueous humor from the anterior chamber to the sub-scleral space. Cataract surgery will be performed with phacoemulsification.
  • Device: Hydrus Microstent with Cataract Surgery — Patients will be randomized to receive either a Hydrus Microstunt or a MINIject implant in conjunction with cataract surgery. If randomized to Hydrus Microstent, the device will be implanted into Schlemm's canal through the trabecular meshwork in order to dilate and restore the natural aqueous outflow pathway through Schlemm's canal, leading to a reduction of intraocular pressure. Cataract surgery will be performed with phacoemulsification.

Primary Outcomes

  • Intraocular Pressure After Surgery (Baseline visit to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-03
Completion: 2031-03-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 152 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Graz
Principal Investigators:
  • Ewald Lindner, Prof. (PRINCIPAL_INVESTIGATOR) - Medical University of Graz
Contact Information
Study Contact:
Ewald Lindner, Prof.
+4331638580810
ewald.lindner@medunigraz.at
Lena M Haiden, MD
+4331638530798
lena.haiden@medunigraz.at
Ewald Lindner, Prof.
+4331638580810
ewald.lindner@medunigraz.at
Medical University Graz
Interventions
  • Device: MINIject with Cataract Surgery — Patients will be randomized to receive either a MINIject implant or a Hydrus Microstunt in conjunction with cataract surgery. If randomized to MINIject, the device will be implanted into the supraciliary space with a minimally invasive ab interno approach. It is designed to be implanted with its head in the anterior chamber and its body in the supraciliary space, leading to improved natural uveoscleral outflow by directing aqueous humor from the anterior chamber to the sub-scleral space. Cataract surgery will be performed with phacoemulsification.
  • Device: Hydrus Microstent with Cataract Surgery — Patients will be randomized to receive either a Hydrus Microstunt or a MINIject implant in conjunction with cataract surgery. If randomized to Hydrus Microstent, the device will be implanted into Schlemm's canal through the trabecular meshwork in order to dilate and restore the natural aqueous outflow pathway through Schlemm's canal, leading to a reduction of intraocular pressure. Cataract surgery will be performed with phacoemulsification.
Study Locations (1 sites)
Medical University Graz, Graz, Styria 8010 Austria
Eligibility Criteria
Inclusion Criteria: * Patients with glaucoma in which surgery is indicated to reach target intraocular pressure as well as lens opacities where CS is indicated * Clinically eligible for both surgeries * Subjects not anticipated to require any further surgery in the next 12 months * Patients' age \> 18 years Exclusion Criteria: * Patients who do not want to make follow-ups at the department * Angle closure, uveitic, neovascular, congenital glaucoma, iridocorneal endothelial syndrome, Axenfeld-Rieger syndrome * Prior filtering glaucoma surgery, suprachoroidal stent, retinal surgery, corneal graft surgery or cyclophotocoagulation * Allergy to any drugs or substances required for the protocol * Pregnant women
Conditions Congenital Diaphragmatic Hernia, Pulmona...
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Congenital diaphragmatic hernia (CDH) occurs in approximately 1 in 3000 US live births, similar to the incidence seen within the Utah Birth Defects cohort. The diaphragmatic defect compromises lung growth and alters pulmonary vascular development. This is reflected postnatally as respiratory failure, pulmonary hypertension (PH) and overall cardiopulmonary dysfunction, particularly post-repair. Currently, optimal management of post-repair PH remains poorly investigated. Sildenafil citrate is a highly selective phosphodiesterase-5 inhibitor that increases cGMP levels, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature. It is used off-label for many neonatal PH disorders, including PH associated with bronchopulmonary dysplasia and idiopathic persistent PH. Most neonates with CDH born within the Mountain West referral basin are managed at a quaternary care center, Primary Children's Hospital (PCH). Of these neonates with PH, approximately 25% have been treated with off-label sildenafil. However, neither the PCH clinical care group nor others have developed/published a standardized approach for either initiating or discontinuing sildenafil therapy in this group of patients. Thus, the aim of this study is to assess the safety and effectiveness of sildenafil therapy for PH in neonates with CDH within the Utah cohort. Given the relatively short-term outcome and small sample size for this trial, the plan is to use this data to support a larger multicenter randomized trial targeting long-term cardiopulmonary outcomes of infants with CDH and post-repair PH.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Sildenafil Oral Suspension — Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
  • Other: Placebo — Equal volume of placebo

Primary Outcomes

  • Change in Left Ventricular Eccentricity Index (LVEI) on echocardiogram after 14 days of study treatment compared to baseline echocardiogram as compared to placebo. (14 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-09-15
Completion: 2026-09-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Contact Information
Study Contact:
Carrie A Rau, RN
801-213-3360
carrie.rau@hsc.utah.edu
Michelle Yang, MD
801-581-7052
michelle.yang@hsc.utah.edu
Primary Children's Hospital
Kimberlee Weaver-Lewis, RN
801-507-7675
kimberlee.weaverlewis@imail.org
Primary Children's Hospital
Interventions
  • Drug: Sildenafil Oral Suspension — Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
  • Other: Placebo — Equal volume of placebo
Study Locations (1 sites)
Primary Children's Hospital, Salt Lake City, Utah 84113 United States
Eligibility Criteria
Inclusion Criteria: * Infants admitted to PCH NICU * Diagnosis of congenital diaphragmatic hernia (CDH) * Status post-surgical repair of diaphragmatic defect * Has an echocardiogram 48-72 hours after repair with left ventricular eccentricity index (LVEI) ≥ 1.4 * Parental consent obtained within 24 hours after the above echocardiogram Exclusion Criteria: * Infants with CDH who do not undergo surgical repair * Does not have an echocardiogram 48-72 hours post-repair * Has LVEI \< 1.4 on above echocardiogram * Has concurrent severe congenital heart defect that requires neonatal cardiac repair * Has a documented sildenafil allergy * Concurrent therapy with fluconazole at time of study drug initiation * Inability to obtain parental consent within 24 hours of the echocardiogram * Receiving extracorporeal membrane oxygenation (ECMO) at the time of the study